CSPG4 and metastatic melanoma: This is a very promising finding for clinical application as targeting of CSPG4+ primary and metastatic melanoma cells can be facilitated via trans stimulation through abundantly available bystanding or even tumor-infiltrating CD20-expressing B cells (31).